These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11737761)

  • 21. Interleukin-2 receptor antagonists for pediatric liver transplant recipients: a systematic review and meta-analysis of controlled studies.
    Crins ND; Röver C; Goralczyk AD; Friede T
    Pediatr Transplant; 2014 Dec; 18(8):839-50. PubMed ID: 25283839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.
    Hirose R; Roberts JP; Quan D; Osorio RW; Freise C; Ascher NL; Stock PG
    Transplantation; 2000 Jan; 69(2):307-11. PubMed ID: 10670644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basiliximab reduces acute liver allograft rejection in pediatric patients.
    Strassburg A; Pfister ED; Arning A; Nashan B; Ehrich JH; Melter M
    Transplant Proc; 2002 Sep; 34(6):2374-5. PubMed ID: 12270443
    [No Abstract]   [Full Text] [Related]  

  • 24. Anti-interleukin-2 receptor antibodies for the prevention of rejection in liver transplant recipients: a systematic review and meta-analysis.
    Zhang Y; Jin W; Cai X
    Ann Med; 2017 Aug; 49(5):365-376. PubMed ID: 27813419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Monoclonal antibodies in renal transplantation].
    Bonvoisin C; Weekers L; Grosch S; Krzesinski JM
    Rev Med Liege; 2009; 64(5-6):287-92. PubMed ID: 19642461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of immunosuppressive regimen on acute rejection and liver graft function.
    Ziolkowski J; Paczek L; Niewczas M; Senatorski G; Oldakowska-Jedynak U; Wyzgal J; Foroncewicz B; Mucha K; Zegarska J; Nyckowski P; Zieniewicz K; Patkowski W; Krawczyk M; Ziarkiewicz-Wroblewska B; Gornicka B
    Transplant Proc; 2003 Sep; 35(6):2281-3. PubMed ID: 14529915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.
    Pham K; Kraft K; Thielke J; Oberholzer J; Sankary H; Testa G; Benedetti E
    Transplant Proc; 2005 Mar; 37(2):899-902. PubMed ID: 15848569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experience with basiliximab in pediatric liver graft recipients.
    Ganschow R; Lyons M; Grabhorn E; Venzke A; Broering DC; Rogiers X; Hellwege HH; Burdelski M
    Transplant Proc; 2001; 33(7-8):3606-7. PubMed ID: 11750532
    [No Abstract]   [Full Text] [Related]  

  • 29. A review of interleukin-2 receptor antagonists in solid organ transplantation.
    Berard JL; Velez RL; Freeman RB; Tsunoda SM
    Pharmacotherapy; 1999 Oct; 19(10):1127-37. PubMed ID: 10512062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of antibodies against the IL-2 receptor in transplantation.
    Waldmann TA; O'Shea J
    Curr Opin Immunol; 1998 Oct; 10(5):507-12. PubMed ID: 9794841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
    Lin M; Ming A; Zhao M
    Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ten-year cost effectiveness of alternative immunosuppression regimens in cadaveric renal transplantation.
    Schnitzler MA; Woodward RS; Lowell JA; Singer GG; Brennan DC
    Transplant Proc; 1999 May; 31(3B Suppl):19S-21S. PubMed ID: 10330963
    [No Abstract]   [Full Text] [Related]  

  • 33. Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids.
    Asensio M; Margarit C; Chavez R; Ortega J; Charco R; Iglesias J
    Transplant Proc; 2002 Aug; 34(5):1970-1. PubMed ID: 12176650
    [No Abstract]   [Full Text] [Related]  

  • 34. New therapeutic monoclonal antibodies target kidney transplant rejection and cancer.
    Piascik P
    J Am Pharm Assoc (Wash); 1998; 38(3):379-80. PubMed ID: 9654869
    [No Abstract]   [Full Text] [Related]  

  • 35. Selective immunosuppression with daclizumab in liver transplantation with graft-versus-host disease.
    Riñón M; Maruri N; Arrieta A; Fernández JR; Ortiz de Urbina J; García Masdevall MD
    Transplant Proc; 2002 Feb; 34(1):109-10. PubMed ID: 11959211
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
    Van Gelder T; Warlé M; Ter Meulen RG
    Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of basiliximab and daclizumab in kidney transplantation.
    Olyaei AJ; Thi K; deMattos AM; Bennett WM
    Prog Transplant; 2001 Mar; 11(1):33-7; quiz 38-9. PubMed ID: 11357555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Monoclonal interleukin-2 receptor antibodies and their use in clinical kidney transplantation: basiliximab and daclizumab].
    Madsen M; Svendsen UG
    Ugeskr Laeger; 2000 Oct; 162(42):5648-52. PubMed ID: 11059309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Basiliximab decreases the incidence of acute rejection after intestinal transplantation.
    Sudan DL; Chinnakotla S; Horslen S; Iyer K; Fox I; Shaw B; Langnas AN
    Transplant Proc; 2002 May; 34(3):940-1. PubMed ID: 12034250
    [No Abstract]   [Full Text] [Related]  

  • 40. First experience with basiliximab in pediatric liver graft recipients.
    Ganschow R; Broering DC; Stuerenburg I; Rogiers X; Hellwege HH; Burdelski M
    Pediatr Transplant; 2001 Oct; 5(5):353-8. PubMed ID: 11560755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.